Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma

Huvila, Jutta; Laajala, Teemu D.; Edqvist, Per‐Henrik; Mardinoğlu, Adil; Talve, Lauri; Pontén, Fredrik; Grénman, Seija; Carpén, Olli; Aittokallio, Tero; Auranen, Annika

doi:10.1016/j.ygyno.2018.02.016

Cited by 20 publications

(18 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Loss of ASRGL1 expression in the hysterectomy specimen is found to independently predict aggressive disease and poor disease‐specific survival in women with endometrial carcinoma . Less is known about ASRGL1 expression in preoperative samples, but combined low expression of ASRGL1 and PR was recently reported to predict high FIGO stage (III–IV) among women with endometrioid endometrial carcinoma . This is in agreement with our findings where low ASRGL1 levels associate with high FIGO stage, both in the whole patient population and in women with a preoperative low‐risk histology.…”

Section: Discussionsupporting

confidence: 91%

“…The optimal staining evaluation and cut‐off for ASRGL1 need to be standardised before clinical implementation. However, different methods (the staining index versus percentage of cells with positive staining) for evaluation of ASGRL1 expression have been published with very similar results, indicating that ASRGL1 might be a robust biomarker.…”

Section: Discussionmentioning

confidence: 99%

“…High expression of ASRGL1 is reported in several tumours, including breast, ovarian and cervical cancers . In endometrial carcinoma, ASRGL1 is reported to be a strong biomarker, and loss of gene and protein expression of ASRGL1 has been found to associate with features of aggressive disease and poor survival . Still, the biological importance of ASRGL1 in normal tissues and during cancer development is largely unknown.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Asparaginase‐like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study

Fonnes

Trovik

Edqvist

et al. 2018

BJOG

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Asparaginase‐like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study

Fonnes

Trovik

Edqvist

et al. 2018

BJOG

View full text Add to dashboard Cite

show abstract

“…Endometrial cancer (EC) is the most common gynecological cancer in women in developed countries [1] and most cases are diagnosed in the early stage [2]. Despite high overall survival rate associated with EC, recurrences occur in more than 10% of patients with early stage disease if adjuvant therapy is not administered [3][4][5], and some do not survive 5 years. Various classification systems have been developed to determine the risk of recurrence, to predict prognosis and to guide therapy in EC.…”

Section: Introductionmentioning

confidence: 99%

The prognostic significance of serum CA125 levels with ER, PR, P53 and Ki-67 expression in endometrial carcinomas

et al. 2019

View full text Add to dashboard Cite

Objectives:The present study evaluates the relationship between the expression levels of hormone receptors (HRs), Ki-67, p53 and serum cancer antigen 125 (CA125) levels in endometrial cancer and clinicopathological risk factors, and determines their prognostic values. Material and methods:This retrospective study included 49 patients with endometrial cancer whose estrogen receptor (ER) and progesterone receptor (PR) Ki-67 and p53 expression levels were determined through immunohistochemical methods, and whose preoperative serum CA125 levels were measured. These factors relationship with various clinicopathological factors, progression-free survival (PFS) and overall survival (OS) was investigated. Results:The study included 49 patients with EC with a mean age of 61 ± 10 years. The rate of HR positivity was significantly higher in the endometrioid histology group than in the non-endometroid histology group (p = 0.026). A high level of Ki-67 expression was found to be associated with a non-endometroid histology (p = 0.016), and a high tumor grade (p < 0.001) and a high p53 expression were found to be associated with advanced disease stage (p = 0.026). A positive correlation was found between p53 and Ki-67, a negative correlation was found between p53 and Ki-67 and the presence of HR. Significant relationship was not found between HR status, p53, Ki-67, CA125 and either other clinicopathological risk factors or survival. Conclusions:While HR positivity indicates favorable clinicopathological prognostic factors, high Ki-67 and high p53 expression indicate unfavorable ones. However, no direct effect of these factors on prognosis was found in this study.

show abstract

“…With the aid of immunohistochemical staining ( 36 – 38 ), prognostication of EMC may be achieved to a greater extent. In order to predict EMC with aggressive potential, which appears to increase in association with patient age, the ‘ER (−) and p53 (+)’ pattern may become an easily applicable indicator.…”

Section: Discussionmentioning

confidence: 99%

Preponderance of endometrial carcinoma in elderly patients

Ogane¹,

Hori²,

Yano

et al. 2018

mol clin onc

View full text Add to dashboard Cite

Elderly patients with endometrial carcinoma (EMC) are considered to have a poor clinical outcome. The present study included 79 patients aged ≥70 years with EMC stage I or II according to the International Federation of Gynecology and Obstetrics classification, and it was conducted to analyse the clinicopathological significance of histological type (I or II), depth of myometrial invasion (<1/2 or ≥1/2), lymphovascular invasion (+ or -) and immunohistochemical profile. The aim of these analyses was to determine whether these factors may adversely affect the patient outcome and the underlying mechanisms. The immunohistochemical markers used were estrogen receptor (ER), Ki-67 and p53. The expression of these markers was evaluated as high (+) or low (−). Accordingly, the patients were divided into groups as follows: 54 cases type I vs. 25 cases type II; 48 cases with myometrial invasion <1/2 vs. 31 cases without myometrial invasion ≥1/2; 63 cases with lymphovascular invasion vs. 16 cases without lymphovascular invasion; 57 cases with ER (+) vs. 22 cases with ER (−); 24 cases with Ki-67 (+) vs. 55 cases with Ki-67 (−); and 29 cases with p53 (+) vs. 50 cases with p53 (−). In conclusion, close attention must be paid to elderly patients with EMC due to the tumor's intrinsic aggressiveness, which may include the ER (−) and p53 (+) pattern as an independent poor prognostic factor.

show abstract

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma

Abstract: P53 and ASRGL1 immunoprofiling stratifies EEC patients into three risk groups with significantly different outcomes. This simple and easily applicable panel could provide a useful tool in EEC risk stratification and guiding the allocation of treatment modalities.

Cited by 20 publications

References 42 publications

Asparaginase‐like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study

Asparaginase‐like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study

The prognostic significance of serum CA125 levels with ER, PR, P53 and Ki-67 expression in endometrial carcinomas

Preponderance of endometrial carcinoma in elderly patients

Contact Info

Product

Resources

About